Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

REGENERON PHARMACEUTICALS, INC.

(REGN)
  Report
Real-time Estimate Cboe BZX  -  12:27 2022-10-04 pm EDT
733.32 USD   -0.25%
10/03Regeneron Pharmaceuticals : Management Change/Compensation - Form 8-K
PU
10/03US Stocks Rally After ISM Manufacturing Data; Crude Oil Jumps
MT
10/03US Stocks Start New Quarter Higher as Government Bond Yields, Manufacturing Gauge Drop
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Regeneron Says its EYLEA Injection Supplemental Biologics License Application Has Been Accepted by the US FDA for Review

06/29/2022 | 07:52am EDT


© MT Newswires 2022
All news about REGENERON PHARMACEUTICALS, INC.
10/03Regeneron Pharmaceuticals : Management Change/Compensation - Form 8-K
PU
10/03US Stocks Rally After ISM Manufacturing Data; Crude Oil Jumps
MT
10/03US Stocks Start New Quarter Higher as Government Bond Yields, Manufacturing Gauge Drop
MT
10/03Insider Sell: Regeneron Pharmaceuticals
MT
10/03US Stocks Advance Midday After ISM Manufacturing Data; Crude Oil Advances
MT
10/03Goldman Sachs Raises Regeneron Pharmaceuticals Price Target to $970 From $796, Maintain..
MT
10/03Regeneron - aflibercept 8 mg positive pivotal results in diabetic macular edema and wet..
AQ
10/03Regeneron Pharmaceuticals, Inc. : Change in Directors or Principal Officers (form 8-K)
AQ
10/03Regeneron Elects Dr. Craig B. Thompson to Board of Directors
PR
10/03Regeneron Elects Craig B. Thompson to Board of Directors and Technology Committee of th..
CI
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 11 824 M - -
Net income 2022 3 884 M - -
Net cash 2022 5 450 M - -
P/E ratio 2022 21,0x
Yield 2022 -
Capitalization 78 592 M 78 592 M -
EV / Sales 2022 6,19x
EV / Sales 2023 5,44x
Nbr of Employees 10 715
Free-Float 80,6%
Chart REGENERON PHARMACEUTICALS, INC.
Duration : Period :
Regeneron Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 735,13 $
Average target price 756,91 $
Spread / Average Target 2,96%
EPS Revisions
Managers and Directors
Leonard S. Schleifer Chairman, Co-President & CEO
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
Robert E. Landry Chief Financial Officer & Executive VP-Finance
P. Roy Vagelos Chairman
Neil Stahl SVP-Preclinical Development
Sector and Competitors
1st jan.Capi. (M$)
REGENERON PHARMACEUTICALS, INC.16.41%78 592
VERTEX PHARMACEUTICALS35.44%76 279
BIONTECH SE-46.98%33 216
WUXI APPTEC CO., LTD.-39.54%29 067
GENMAB A/S-2.85%22 039
ARGENX SE14.65%19 582